Are you a Knight ADRC affiliated researcher with a news article you would like us to post?
Contact Us
Anti-amyloid drug shows signs of preventing Alzheimer’s dementia (Links to an external site)
Clinical trial of people destined to develop early-onset Alzheimer’s disease shows eliminating amyloid from brain may prevent symptoms, supports need for confirmatory studies.
Researchers find a hint at how to delay Alzheimer’s symptoms. Now they have to prove it (Links to an external site)
An experimental treatment appears to delay Alzheimer’s symptoms in some people genetically destined to get the disease in their 40s or 50s, according to new findings from ongoing research now caught up in Trump administration funding delays.
$4.5 million supports pathbreaking neuroimmunology research (Links to an external site)
Washington University School of Medicine in St. Louis has received a three-year $4.5 million grant from the Carol and Gene Ludwig Family Foundation, aimed at advancing research on neuroimmunology and neurodegeneration with the ultimate goal of developing new treatments for Alzheimer’s disease.
Patient defies genetic fate to avoid Alzheimer’s (Links to an external site)
Doug Whitney, who lives near Seattle, Wash., inherited a mutation that has caused many family members to develop Alzheimer’s disease at about age 50, yet he shows no sign of the illness at age 75. His case is the subject of a new study by WashU Medicine researchers that aims to identify potential routes to preventing or treating Alzheimer’s based on Whitney’s exceptional resilience to the disease.
Two Alzheimer’s drugs help patients live independently at home for longer periods (Links to an external site)
Lecanemab (Leqembi) and donanemab (Kisunla) could slow cognitive decline, but side effects exist.